Also noteworthy earlier this month was the publication of a Phase 2 randomized trial in 272 participants without diabetes of orforglipron, an oral GLP-1 agonist, which achieved a 14.7% weight loss (placebo-adjusted 12.3%) at the highest dose With that brief review of the latest trials and drugs, lets turn to clinical outcomes, for which most are taking us back to single agonistGLP-1drugs
Exercise regularly and aim for at least 30 minutes of moderate exercise most days of the week
Diabetic patients have reported experiencing worsening blood sugar spikes and higher blood sugar levels than before they started taking the drug
Although both of these drugs have the same purpose, you might wonder what if the two drugs were taken together
The educational content can say why those topics are outside scope
Prior to semaglutide treatment, 30% of the subjects were treated with insulin, and 31% were treated with another GLP-1 RA (glucagon-like peptide-1 receptor agonist